vimarsana.com
Home
Live Updates
NurExone Biologic Inc.: NurExone Reports Second Quarter 2022
NurExone Biologic Inc.: NurExone Reports Second Quarter 2022
NurExone Biologic Inc.: NurExone Reports Second Quarter 2022 Financial Results and Provides Business Update
Calgary, Alberta--(Newsfile Corp. - August 25, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp.) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided
Related Keywords
New York ,
United States ,
Canada ,
United Kingdom ,
Toronto ,
Ontario ,
Israel ,
Singapore ,
Vancouver ,
British Columbia ,
Canadian ,
James Jay Richardson ,
Canaccord Genuity ,
Lior Shaltiel ,
Oded Orgil ,
Jay Richardson ,
Clarkson Gordon Arthur Young ,
Advisory Services ,
Twitter ,
Enerspar Corp The Company Or Nurexone ,
Polyrizon Ltd ,
Royal Canadian Academy Mr ,
Canada Israel Chamber ,
Insolvency Practitioner Association Of The United Kingdom ,
Nurexone Biologic Inc ,
Facebook ,
York University ,
Alberta Newsfile Corp ,
Venture Exchange ,
Medigus Ltd ,
Merrill Lynch ,
Targus Corporation ,
Drug Administration ,
University Of Western Ontario ,
Adcore Inc ,
Technion University ,
Youtube ,
Ernst Young ,
Israel Institute Of Technology ,
Manulife Financial ,
Research Agreement ,
Exone Biologic ,
Enerspar Corp ,
Chemistry Manufacturing ,
Pre Investigational New Drug ,
Intellectual Property ,
Spinal Cord Injury ,
Reverse Takeover Transaction ,
Extracellular Vesicles ,
Central Nervous System ,
Patent Cooperation Treaty ,
Sponsor Research Agreement ,
Collaboration Agreement ,
Canadian Chartered Accountant ,
Singapore Certified Public Accountant ,
Insolvency Practitioner Association ,
Interim Chairman ,
Royal Canadian Academy ,
Capital Markets ,
Financial Advisor ,
Senior Executive ,
Gravitas Securities ,
San Jose ,
Bay Street ,
Western Ontario ,
Political Science ,
Quarter Fiscal ,
Services Shares ,
Israel Institute ,
Executive Officer ,
Nurexone ,
Biologic ,
Reports ,
Second ,
Quarter ,
022 ,
Financial ,
Results ,
Rovides ,
Business ,
Update ,